HALISTER: Novartis 3Q Core EPS Beats, Net Sales in Line; Keeps FY Outlook

Novartis 3Q Core EPS Beats, Net Sales in Line; Keeps FY Outlook

(Bloomberg) -- For 2016, co. still expects core operating income will be broadly in line or decline at a low single digit percentage at constant FX; net sales expected to be broadly in line with prior year.
  • 3Q net sales: $12.1b vs est. $12.2b
  • 3Q core EPS: $1.23 vs est. $1.20
  • 3Q core operating income (ebit): $3.38b vs est. $3.23b
  • 3Q core net income: $2.94b vs est. $2.85b
    • (Estimates are continuing operations in local currency, not constant FX)
  • Webcast/conf call at 2pm CET; dial-in: +41 22 592 71 03
  • Statement
  • NOTE: Yesterday, PREVIEW Novartis 3Q: Gleevec Erosion, Alcon, Entresto to Weigh
Alert: HALISTER
Source: BFW (Bloomberg First Word)

Tickers
NOVN VX (Novartis AG)

To de-activate this alert, click here

UUID: 7947283